Drug intelligence / Profile preview

LUC-201

Development stage: Preclinical
Lead developer: Lucina Biotherapeutics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

LUC-201 is a preclinical-stage live biotherapeutic product (LBP) being developed by Lucina Biotherapeutics for the treatment of dry age-related macular degeneration (AMD) and Stargardt Type 3 Macular Dystrophy. Developed using the PUFActive™ platform, LUC-201 consists of engineered microorganisms designed to function as "oral biofactories." Upon oral administration, these microbes produce very long-chain polyunsaturated fatty acids (VLC-PUFAs) within the gastrointestinal tract to restore systemic and retinal lipid levels. This approach aims to rejuvenate retinal cells and reverse aging-related dysfunction caused by the decline of critical lipids over time, specifically targeting the lipid deficiencies associated with macular dystrophies.

Beyond the preview

Go deeper on LUC-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LUC-201.

Explore the full profile